OmniAb (OABI) Net Income towards Common Stockholders Growth (1y) (2022 - 2026)
OmniAb (OABI) Net Income towards Common Stockholders Growth (1y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
-58.11% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
104.24% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-290.15% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
-129.68% |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
59.59% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
OmniAb |
293.04 Mn |
250.07 Mn |
14.41 Mn |
57.65% |
| Date | Value |
|---|
| Mar 31, 2026 |
57.65% |
| Dec 31, 2025 |
-8.50% |
| Sep 30, 2025 |
-0.93% |
| Jun 30, 2025 |
-16.46% |
| Mar 31, 2025 |
4.01% |
| Dec 31, 2024 |
7.01% |
| Sep 30, 2024 |
-4.03% |
| Jun 30, 2024 |
7.45% |
| Mar 31, 2024 |
-210.84% |
| Dec 31, 2023 |
-306.06% |
| Sep 30, 2023 |
-3,090.44% |
| Jun 30, 2023 |
-1,032.98% |
| Mar 31, 2023 |
-66.26% |
| Dec 31, 2022 |
2,924.40% |
| Sep 30, 2022 |
-845.26% |
| Jun 30, 2022 |
-59,393.50% |
| Mar 31, 2022 |
-47,022.94% |
